There is a bidirectional association between OSA and systemic hypertension. The strengths of this relationship appear to be modulated by factors such as age, sex, and somnolence. The 24-h BP circadian pattern also appears to be infl uenced by OSA. Patients with this syndrome exhibit a high prevalence of nondipping or riser circadian patterns, which are related to clinical and subclinical organ damage in the heart and brain. However, the infl uence of OSA on 
Epidemiologic data suggest that there is a strong association between OSA and systemic hypertension, with important implications for cardiovascular outcomes. Th ere is a high prevalence of OSA in hypertensive individuals (30%-50%). 4 If we consider only patients with resistant hypertension, then a dramatic increase in prevalence, reaching 83%, is observed. 5 Th e epidemiologic relationship between hypertension and OSA is bidirectional. Not only do patients with hypertension appear to be more likely to suff er OSA, data from community and population studies indicate that patients with OSA present a high prevalence of hypertension. 6 -8 Th e prevalence of hypertension in patients with moderate or severe OSA was reported to be 46% or 53%, respectively. 8 The results of experimental studies describe pathophysiologic features that support a causal, bidirectional relationship between OSA and hypertension. On the one hand, mechanisms based on sympathetic and reninangiotensin-aldosterone activation, as well as oxidative stress and endothelial dysfunction, implicate OSA as an independent cause of hypertension. 1 On the other hand, acute increases in BP may cause an inhibition of the upper airway muscles. This phenomenon, together with volume overload and its displacement to the upper body during sleep, which can be experienced by subjects with hypertension and can lead to pharyngeal edema, may explain the link between hypertension and OSA. 9 -11 In addition to these observations, the purpose of this review of OSA and hypertension is to present an overview of state-of-the-art strategies that address issues that may be relevant to daily clinical practice.
OSA and the Incident Risk of Hypertension
Epidemiologic studies show that patients with OSA have a high prevalence of obesity. 2 , 11 Th erefore, obesity may be the nexus that explains the high prevalence of hypertension in these patients. However, the results of a large, prospective, longitudinal study, the Wisconsin Sleep Cohort Study (WSCS), suggest that moderate to severe OSA (apnea-hypopnea index [AHI] Ն 15/h) is an independent cause of hypertension. Subjects with this degree of OSA severity showed a 3.2-fold increase in the odds of developing hypertension, compared with subjects without OSA. 12 Th e WSCS results impacted the American guidelines for the management of hypertension (Th e Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [JNC VII] ), and OSA was recognized as the first secondary cause of hypertension. 13 Similarly, Marin et al 14 conducted an observational study that included 1,889 subjects without hypertension who were admitted to a sleep clinic and were followed up for a mean of 10.1 years. Th e authors found an increased incidence of hypertension in subjects with untreated OSA, compared with treated patients. Other studies have shown that age, somnolence, and sex could infl uence and modulate this independent relation. Bixler et al 15 examined 741 men and 1,000 women aged 20 to 100 years and found that the strength of the association between OSA and hypertension may become attenuated with age. Haas et al 16 confi rmed these results and established a cutoff age of 60 years. Above this age, the strength of the association declines. Conversely, the results of a 5-year follow-up of participants in the Sleep Heart Health Study (SHHS), 17 aft er adjusting for BMI, did not confi rm the independent relationship between OSA and hypertension found in the Wisconsin cohort.
One of the most accepted explanations for these diff erences is the divergence between the characteristics of the two cohorts, particularly in terms of age. Subjects from the SHHS were signifi cantly older than those from the WSCS (60 years vs 47 years old). Data reported by Kapur et al 18 showed that an increase in daytime somnolence, measured with the Epworth Sleepiness Scale, correlated positively with a stronger association between OSA and the risk of hypertension. In addition, the eff ect of CPAP treatment on the incidence of hypertension has been evaluated in nonsleepy patients. In a randomized controlled trial (RCT) that included 725 subjects with a median follow-up of 4 years, the Spanish Sleep and Breathing Network found that CPAP did not reduce the incidences of hypertension or cardiovascular events in nonsleepy subjects. 19 These data again suggest that the presence or absence of sleepiness may influence the risk of incident hypertension. Finally, in a populationbased case-control study, Hedner et al 20 found that the association may be more evident in men than in women.
Despite all these considerations, the association between OSA and the incident risk of hypertension remains unresolved. Th e Vitoria Sleep Cohort (VSC) 21 followed, for 7.5 years, 1,180 subjects aged 30 to 70 years who were not hypertensive. Th e results did not suggest an association between OSA and the incidence of hypertension aft er adjusting for age, sex, and BMI. Th ese discordant results, in comparison with those of the WSCS, may be explained by two critical features: diff erences in population characteristics, especially in terms of BMI and sex, and diff erences in the diagnostic procedure used. Th e subject samples in the WSCS were more obese (BMI of 29 kg/m 2 compared with 26 kg/m 2 in the VSC) and included more men (56% compared with 48% in the [ 1 4 8 # 3 C H E S T S E P T E M B E R 2 0 1 5 ] VSC). However, variation in the sleep study procedures, with polysomnography applied in the WSCS and home polygraphy in the VCS, may be the most relevant diff erence. Polygraphy shows good concordance with polysomnography in moderate to severe OSA, 22 but this eff ect has not been observed in normal and mild OSA. Th e majority of the subjects in the VSC had no or mild OSA. Among the 1,180 patients included in the study, 377 patients had OSA at baseline, and proportionately few, 149 subjects, had a respiratory disturbance index that was Ն 14/h.
It is important to consider several potential methodologic diff erences in the studies that have examined BP and OSA. These differences should be considered when comparing the results from different studies. For example, the following components of the studies can vary: definition of hypertension, BP measurement methodology (patient position, time of day, technique), controlling for medications, definition of sleepiness based on multiple sleep latency tests or the Epworth Sleepiness Scale, and definition of OSA based on an AHI assessed by polysomnography or polygraphy. Moreover, several studies have suggested that the degree of hypoxemia could play an important role beyond AHI. Accounting for all of these considerations, we conclude that OSA is an independent cause of hypertension but with less signifi cance than initially suspected.
Circadian Pattern of BP in Patients With OSA Studies involving 24-h ambulatory BP monitoring (ABPM) have shown that subjects with hypertension with a decrease in BP of , 10% during the night (nondippers) and those who present an increase in BP at night (risers) 23 exhibit greater organ damage and worse cardiovascular outcomes than do subjects with hypertension who present a decrease of . 10% during the night (dippers). 24 , 25 Initial case-control studies using 24-h ABPM showed that patients with OSA had a high prevalence of an unfavorable circadian pattern, compared with subjects without OSA. 26 One study found that 84% of patients with mild to severe OSA had a nondipper circadian pattern. 27 Similarly, Ancoli-Israel et al 28 studied 140 patients with hypertension and found that patients with OSA had a higher dipping ratio, defi ned as the ratio between the mean nighttime BP and the mean daytime BP, compared with subjects without OSA. Data from a 328-subject subsample of the WSCS, with an average of 7.2 years of follow-up, showed that there was a dose-response relationship between increased odds of developing a nondipping systolic BP (SBP) and the severity of OSA at baseline. 29 Th ese results suggest that there is a causal link between OSA and an altered circadian pattern.
Th e presence of a high nocturnal BP, defi ned as a nighttime BP Ն 120 mm Hg (SBP) and/or 70 mm Hg (diastolic BP [DBP]), is the most important BP prognostic variable for cardiovascular outcomes, 30 -32 and it has shown strong correlations with subclinical brain 33 , 34 and heart damage. 35 Th us, the presence or absence of nighttime hypertension on ABPM analysis may be more important than the circadian pattern. In an initial study of 2,877 subjects, Cuspidi et al 36 found a positive relationship between the nondipper pattern and left ventricular hypertrophy. However, a second study 37 examined heart damage in patients with nocturnal hypertension, compared with dippers and nondippers, and no diff erences were detected. These results suggest that, rather than the circadian pattern, the critical factor in determining organ damage is the presence or absence of nocturnal hypertension. To date, data are lacking regarding the prevalence of a high nocturnal BP in patients with OSA.
Beat-to-beat BP monitoring studies have provided a deeper analysis of nocturnal BP in patients with OSA. 38 , 39 Th ese small studies (examining beat-to-beat BP and OSA) found that during apnea events in patients with severe OSA, a dramatic increase in SPB from baseline could develop. Unfortunately, the conditions in which ABPM must be performed make this tool unable to capture these BP fl uctuations. Organ damage consequences related to this increase in SBP could be expected, but the magnitude of this eff ect in patients with hypertension has still not been elucidated. Additionally, CPAP treatment, and its protective effect against these BP increases, may be benefi cial in this context.
OSA and Resistant Hypertension
Resistant hypertension is defi ned as the clinical situation in which lifestyle changes plus pharmacologic treatment with three drugs (including a diuretic) fail to lower the BP to below 140/90 mm Hg. 23 , 40 Depending on the population studied, the prevalence of this condition ranges from 5% to 30% of subjects with hypertension. 40 Th e reported data have shown a high prevalence of OSA in patients with resistant hypertension (71%-83%). 5 , 41 In a study that included 125 subjects with resistant hypertension, Pedrosa et al 42 found that OSA was the most frequent condition related to resistant hypertension (64%). In fact, OSA showed a much greater association with resistant hypertension than with primary hyperaldosteronism (5.6%). Demede et al 43 found that patients with resistant hypertension had a 2.5-times increased risk of OSA compared with other subjects with hypertension. Th e high level of aldosterone in resistant hypertension and its consequences in terms of volume overload and rostral fl uid shift during sleep, which lead to secondary pharyngeal edema that increases upper airway obstruction, have been hypothesized to be the mechanisms that underlie the link between hypertension and OSA. 10 , 44 The 40 Organ damage in resistant hypertension has been well established, but the impact of the coexistence of OSA on this damage and on the cardiovascular outcomes of patients with resistant hypertension must be clarifi ed.
Eff ect of OSA Treatment on Hypertension

CPAP Treatment
Many studies have evaluated the eff ect of CPAP treatment on BP in patients with OSA ( Fig 1 ) . However, most of these studies evaluated short-term effects and had important limitations and design diff erences. 45 Th ese differences and limitations can be divided into two categories. One set of factors depends on the study population, such as age, sex, BMI, hypertension degree, and adequate antihypertensive treatment, as well as OSA severity. Another set of factors depends on the methodology, such as the number of subjects included, whether the study had a multicenter or a single-center design, the treatment used in the control group (sham-CPAP use or not), the hypertension defi nition used, how the evaluation of the eff ect on BP was conducted (offi ce BP or ABPM), and the variability in follow-up time or CPAP compliance. Despite these handicaps, several metaanalyses 45 -52 have demonstrated a concordant mild eff ect of CPAP on BP, with a drop of approximately 2 mm Hg ( Table 1 46 -54 ) . Th is eff ect is signifi cantly inferior to those achieved by most of the commonly used antihypertensive drugs. Despite this modest decrease, this eff ect is not negligible and could have benefi cial eff ects on cardiovascular outcomes. 55 Moreover, similar to the eff ects of certain antihypertensive drugs, an increase in protective organ damage beyond that associated with the observed BP reduction cannot be excluded.
Certain variables, such as CPAP compliance, 50 , 51 , 53 , 56 somnolence status, 51 , 53 and baseline BP, 50 , 52 may modulate the strength of the eff ect of CPAP treatment on BP. Th e decrease in BP achieved by CPAP treatment is clearly related to the hours of CPAP use and likely to its use during rapid eye movement sleep. 57 In relation to symptoms, a recent meta-analysis found no eff ect of CPAP on BP in patients without somnolence. 53 Another characteristic is the infl uence of OSA severity on BP drop magnitude during CPAP treatment. Two meta-analyses found a relationship between OSA severity and the magnitude of the drop in BP during CPAP treatment. 49 , 51 Conversely, Montesi et al 50 showed an independent relation between OSA severity and BP reduction. A later patient-level meta-analysis, using individual patient data from the trials, confi rmed these results. 52 Lifestyle modifi cations, including weight loss, should be recommended in patients receiving hypertension treatment. 23 Chirinos et al 58 randomized 181 patients with obesity and moderate to severe OSA to three possible interventions for 24 weeks: CPAP treatment alone, weight-loss intervention alone, and CPAP plus weightloss intervention. Among 136 patients who completed the study, in the per-protocol population, the reduction in SBP at 24 weeks was greater in the combined intervention group (14.1 mm Hg) than in the weight-loss group (6.8 mm Hg) or in the CPAP group (3.0 mm Hg). Th e reduction in mean arterial pressure was also significantly greater in the combined treatment group. Th us, the combined treatment reduced BP more than either intervention alone. Th ese results suggest the possibility of an interaction eff ect between lifestyle modifi cations, weight-loss measures, and CPAP in the control of BP.
In patients with resistant hypertension, CPAP treatment showed a clearer drop in BP compared with other subjects with hypertension. 56 , 59 -63 A recent meta-analysis 54 showed that the eff ects of CPAP in patients with resistant hypertension on the drop in ambulatory BP were 2 7.21 (95% CI, 2 9.04 to 2 5.35; P , .001; I 2 , 58%) and 2 4.99 (95% CI, 2 6.01 to 2 3.96; P . .001; I 2 , 31%) for SBP and DBP, respectively. Considering only the results from RCTs, the mean net changes in ambulatory BP were 2 6.74 mm Hg (95% CI, 2 9.98 to 2 3.49; P , .001; I 2 , 61%) and 2 5.94 mm Hg (95% CI, 2 9.40 to 2 2.47; P 5 .001; I 2 , 76%) for SBP and DBP, respectively, favoring the CPAP groups ( Table 2 ) . Th e study that provided the 56 which included 194 patients. In that study, a signifi cant reduction in 24-h BP of 4.4 mm Hg (95% CI, 1.8-7; P 5 .001) was observed, and this reduction was more evident at night. This reduction was assessed according to CPAP tolerance and compliance (perprotocol analysis). Th e linear regression analysis showed that BP improved by 1.3 mm Hg for each additional hour of CPAP use. Th e HIPARCO study also showed that CPAP use led to the recovery of the normal circadian pattern, with a secondary potential cardiovascular benefi t. However, there was signifi cant variability in the BP drop among subjects, and the factors that infl uence the BP response to CPAP in patients with resistant hypertension have not been identified. Thus, there is a need for long-term RCTs to provide relevant information regarding the cost eff ectiveness of CPAP treatment in the management of resistant hypertension in these patients.
Oral Appliances
Oral appliances are a recommended treatment of patients with mild to moderate OSA. Currently, the studies that have evaluated the eff ects of this treatment on BP have included small patient sample sizes. In a meta-analysis of seven studies that included a total of 399 patients, Ift ikhar et al 64 found that oral appliance treatment in subjects with hypertension and OSA provided a BP reduction that was similar to that achieved with CPAP. Th e mean changes were 2 2.7 mm Hg (95% CI, 2 8.5 to 2 4.6; P 5 .04) for SBP, 2 2.7 mm Hg (95% CI, 2 0.9 to 2 4.6; P 5 .004) for DBP, and 2 2.40 mm Hg (95% CI, 2 4.01 to 2 0.80; P 5 .003) for BP. An important limitation of this meta-analysis is that most of the included studies were observational. Therefore, the authors recommended that these results be confi rmed by performing RCTs with large patient samples.
Eff ects of Hypertension Treatment on OSA
According to the available physiopathologic knowledge of the relationship between OSA and hypertension, antihypertensive drugs that modulate sympathetic activity and the renin-angiotensin-aldosterone axis may be the best treatment options for hypertension in patients with OSA. To date, the studies that have evaluated the eff ects of antihypertensive drug treatment on OSA severity have included small subject samples and no comparable populations, and they have had important methodologic diff erences. Th erefore, it is not possible to establish defi nitive recommendations based on the results of the available clinical studies. Previous work has evaluated b -blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers and spironolactone. ACE inhibitors, such as enalapril and cilazapril, 65 , 66 and b -blockers, such as atenolol, 67 have been shown to control nighttime BP in patients with OSA. Th e classic study was conducted by Kraiczi et al, 67 who evaluated the fi ve most commonly used antihypertensive drugs (atenolol, amlodipine, enalapril, losartan, and hydrochlorothiazide) and their effects on AHI (OSA severity). Th ey did not detect any variations in OSA severity according to the drug used, but the study was underpowered to allow for a comparison of the drugs, and it lacked a placebo control.
Data from other studies have provided controversial results. On the one hand, some studies with very limited samples executed at single centers with short-term
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follow-ups have shown an improvement in OSA severity in response to treatment with ACE inhibitors (cilazapril), 68 , 69 b -blockers (metoprolol, nebivolol), 69 , 70 and angiotensin receptor blockers (valsartan). 70 On the other hand, other studies have questioned the use of ACE inhibitors in patients with hypertension and OSA because of the side eff ects of these antihypertensive drugs, which may cause rhinopharyngeal infl ammation and increase upper airway obstruction. 71 Additionally, b -blockers can favor weight gain, which may negatively impact the severity of OSA. Most of these negative side eff ects require a long period of time to become evident; thus, the short duration of follow-up in these studies could not rule out their impact on the severity of OSA. Additionally, Nerbass et al 72 reported negative effects of calcium channel blockers that shortened sleep duration.
The most promising class of antihypertensive drug treatment, based on their eff ects on OSA severity and BP, are diuretics, 73 , 74 especially spironolactone. 74 By reducing parapharyngeal edema and secondary upper airway obstruction, these drugs appear to improve OSA severity 74 and to greatly reduce BP. In conclusion, there is a need for well-designed, multicenter, large-sample studies with long follow-up periods to improve our knowledge and allow solid recommendations to be established.
Conclusions and Future Directions
Th ere is an epidemiologic relationship between OSA and hypertension that is especially important in subjects with resistant hypertension. Despite this, the causal relationship between OSA and hypertension is probably not as important as initially thought. Certain population characteristics, such as age, sleepiness associated with OSA, and sex, may be important in determining the role of OSA as a cause of hypertension. OSA may also lead to the development of an unfavorable circadian pattern of BP, with worse cardiovascular outcomes. In addition, some characteristics that are specifi cally linked to the nocturnal BP eff ect of sleep apnea remain to be clarifi ed. 
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